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K. Srinath Reddy, MSC, MD, DMSEE PAGE 2071I n September 2011, the United Nations called forconcerted efforts to reduce global mortalityfrom chronic noncommunicable diseases (NCDs)
(1). In the hopes of achieving this goal, the World
Health Organization adopted 9 targets in May 2013
for prevention and control of NCDs to be reached by
2025 in comparison with the rates of mortality and
risk factor prevalence estimated for 2010. The over-
arching target was a 25% reduction in NCD-related
mortality in those 30 to 70 years of age, yielding the
catchy slogan of “25  25” (2). Cardiovascular diseases
(CVDs) are the leading contributors to these prevent-
able premature deaths but also have the most proven
lifesaving therapies among the NCDs. Thus, the “25 
25” goal can be attained only if primary and second-
ary prevention of CVD is effectively provided to those
at risk in the decade ahead.
A recent study, which modeled the potential
impact of evidence-based interventions targeting 6
risk factors (smoking, alcohol, salt intake, obesity,
blood pressure, and blood glucose level) (3), supports
this hypothesis. The study found that the goal of
“25  25” is attainable for CVD if the target related to
each of those risk factors is reached. However, that
goal will not be accomplished for the larger group of
NCDs unless tobacco consumption is reduced by 50%
(3). Although lipid-lowering interventions and drug
therapy for secondary prevention of CVD were not
included in this model, effective delivery of these
clinical interventions is essential for reaching the
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Guest Editors for this paper.This message is especially pertinent for low- and
middle-income countries (LMICs), which contribute
to 80% of all NCD-related deaths and 90% of NCD-
related deaths that occur in those younger than
60 years of age. A multicountry cohort study observed
that these countries have a higher age standardized
incidence of CVD-related events and mortality than
high-income countries despite having lower levels of
risk factors (4). The importance of efﬁcient health
systems, capable of effectively delivering proven
drugs and revascularization procedures to people who
can beneﬁt from them, was stressed as a major
explanatory factor that high-income countries have
lower mortality rates despite higher risk factor levels.
Despite the obvious case for prioritized action on
secondary prevention, global practice patterns reveal
low levels of prescription and adherence (5,6). This is
an inexcusable failure of the health care system
anywhere but is particularly tragic in LMICs, where
many young lives that could be saved are lost because
the “lifeguard” of secondary prevention was not
deployed. To move secondary prevention from evi-
dence (efﬁcacy) to action (effectiveness), we need to
improve practice patterns of providers, enable uptake
and adherence by patients, and, crucially, reconﬁgure
health systems to reliably deliver chronic continuous
care (7), starting with the primary health care setting.The 2-part FOCUS (Fixed Dose Combination Drug
for Secondary Cardiovascular Prevention) study,
published in this issue of the Journal by Castellano
et al. (8), addresses one of the vexing issues of long-
term care of patients with CVD: low levels of adher-
ence to multidrug therapy. The initial cross-sectional
component of this 5-country study (phase 1) sought
to elucidate the determinants of adherence to therapy
and identify barriers to continued consumption of
lifesaving drugs by patients. The second component
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trolled trial to evaluate the effect of a polypill
(combining 3 drugs in a single tablet) on both patient
adherence to treatment and cardiovascular risk fac-
tors, apart from assessing safety and tolerability (8).
The study was conducted in 3 South American
countries (Argentina, Brazil, and Paraguay) and 2
European countries (Italy and Spain) with widely
varying health systems. Italy and Spain have
government-ﬁnanced universal health coverage and
low levels of private health insurance, whereas the 3
South American countries have varying levels of pa-
tient co-payments and higher levels of private health
insurance as a feature of their mixed health systems.
The affordability of CVD drugs also varies widely.
The study population comprised men and women
40 years of age and older who survived a myocardial
infarction in the previous 2 years.
In phase 1, adherence to 4 prescribed cardiovas-
cular drugs (aspirin, statin, angiotensin-converting
enzyme inhibitor, and beta-blocker) was assessed in
2,118 patients. The investigators used a previously
validated Morisky-Green questionnaire (with a higher
than usual cutoff score of 20 to deﬁne “good adher-
ence”). Several patient characteristics were identiﬁed
as having an adverse inﬂuence on adherence:
younger than 50 years of age, intake of more than 10
pills per day, complex drug regimens involving
nonoral administration of some medications, current
smoking, sedentariness, and depression. In addition,
sociodemographic determinants (lower levels of ed-
ucation, social support, and insurance coverage) and
provider features (general practitioner rather than
cardiologist, private clinic rather than public health
facility) also had an adverse effect. Although some of
these variables were clustered and interactive, an
independent negative association with good adher-
ence was observed with younger age, depression, and
a complex treatment regimen, whereas a positive
association was noted with higher levels of insurance
coverage and social support. The average baseline
measure of good adherence was 45.5% and ranged
widely, from 17% to 50%, across countries.
The trial in phase 2 attempted to address some of
these determinants by using a simpliﬁed drug regi-
men of 3 CVD drugs combined in a single polypill.
This contained aspirin 100 mg, simvastatin 40 mg,
and ramipril in variable doses (2.5 mg, 5 mg, or 10 mg).
It did not include a beta-blocker. The polypill was
provided to the intervention group, with the dose of
ramipril titrated by the physician. The control group
was provided the 3 drugs separately. Across the
5 countries, 695 participants from the phase 1 study
were drawn for random allocation to the 2 groups.A critical feature of the trial is that all the drugs
were “provided” free of cost and not merely “pre-
scribed” to patients in both groups. This was essen-
tial, because the primary research question related to
whether the polypill would result in better adherence
than is now achieved with separate pills. To answer
this, the potential impact of vagaries such as afford-
ability and variable insurance coverage had to be
removed from the trial design. If the polypill indeed
improves adherence due to greater patient accep-
tance, unencumbered by issues of affordability, the
health system can then devise other methods to
eliminate or minimize those barriers through uni-
versal coverage, price control, or other effective
market interventions. To measure good adherence,
the trial used the Morisky-Green questionnaire score
of $20 (as in phase 1) and, in addition, a pill count.
The FOCUS trial found that the 3-drug polypill
improved adherence on 9-month follow-up (50.8%
vs. 41% on an intention-to-treat analysis and 65.7%
vs. 55.7% in a per-protocol comparison). However, no
signiﬁcant differences were observed between the 2
trial arms in either the measured values of mean
systolic blood pressure and low-density lipoprotein
cholesterol (LDL-C) or rates of adverse events and
death. Thus, while the primary endpoint of better
adherence was met, the impact of that on improved
health outcomes (intermediary risk factors or deﬁni-
tive CVD events) could not be shown in a trial of this
size and duration. A double-blind trial of a polypill
(Polycap, Cadilla Pharmaceutical Ltd., New Delhi,
India) also had earlier shown an improvement in CVD
risk factors equivalent to active separately adminis-
tered drugs, except in the case of LDL-C, where the
polypill had a lower effect than the separately
administered simvastatin (9).
Previously, improved adherence to a polypill
strategy for prevention of CVD was shown in the
UMPIRE (Use of a Multidrug Pill in Reducing Cardio-
vascular Events) trial (33% higher than usual care).
This trial, which randomized 2,004 participants with
established CVD or at a high risk for CVD, used a
4-drug ﬁxed combination in 2 variants: one contain-
ing 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril,
and 50 mg atenolol and the other a combination of
75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril,
and 12.5 mg hydrochlorothiazide. At 15 months of
follow-up, small but statistically signiﬁcant differ-
ences were observed in systolic blood pressure and
LDL-C level. Again, no signiﬁcant differences were
observed in serious adverse events or cardiovascular
events (10). In this study, the intervention group had
a free supply of either polypill, whereas the control
group encountered affordability barriers under usual
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better test of the effect of a polypill on adherence,
independent of the impact of affordability.
What are the implications for clinical practice? The
polypill, on its own, improves adherence. If other
barriers to adherence also are removed or lowered
(through improved affordability and social support as
well as treatment of comorbidities such as depres-
sion), there are likely to be even higher beneﬁts.
While a ﬁxed-dose combination is attractive for ease
of prescription, an opportunity for dose titration
would be appealing to the physician. The FOCUS trial
has attempted to provide both features in its polypill.
The UMPIRE trial tested 2 polypills, with potential
for choice customized for different types of CVD
(with beta-blocker for post–myocardial infarction
patients and diuretic substituted for post-stroke/
transient ischemic attack patients). It appears that a
family of polypills will soon emerge for reducing
high CVD risk. This has to be kept small if physician
practice is to be aided by clarity and not eroded by
confusion. Meanwhile, larger trials will need to be
conducted in relatively homogeneous populations
to show an impact on risk factors as well as CVD
events.
The implications for health systems are even more
obvious. All efforts must be made to ensure thatpeople with CVD or at high risk for CVD are covered by
lifesaving CVD drugs and that adherence is promoted
through multiple complementary interventions. The
polypill is a useful contribution that can enhance the
success of those efforts. Pooled public procurement
by the health systems of LMICs of quality-assured,
generically produced, price-controlled polypills will
improve their availability and affordability, especially
when distributed at no cost or low cost at public
health care facilities. This is already happening for
human immunodeﬁciency virus/acquired immuno-
deﬁciency syndrome, tuberculosis, andmalaria. Given
the huge health, economic, and social burdens im-
posed on LMICs by preventable CVD-related death
and disability, the World Health Organization and
LMICs must now accord the same status to the provi-
sion of lifesaving CVD drugs (11–13). Along with mul-
tisectoral policies that act at the population level to
prevent the acquisition or augmentation of CVD risk
factors (“poly-policy”), the polypill can help us reach
the “25  25” goal.
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